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1.1 Multiple sclerosis Multiple  sclerosis  (MS)  is  an  auto‐inflammatory disease  of  the  central  nervous system (CNS)  that  eventually  leads  to neuro‐degeneration. MS affects over one million people worldwide, twice as many women as men, and is the first cause of neurologic disability in young adults(1). For  the  patient,  the  diagnosis  of MS means  a  sentence  to  hardship,  a  storm of uncertain  hopes  and  incomprehensible  certainty  about  future  loss  of  function. MS is a progressive disease that can take various clinical courses. In most cases, there  is  a  progression  towards  accumulation  of  neurological  dysfunction  with relapses and remissions (RR‐MS). During relapses, symptoms commonly include a loss of sensation, coordination or vision. In the beginning of the disease, there is  usually  restitution  ad  integrum  of  neurological  functions,  but  over  time, neurological  impediments  persist  even  during  the  remission  phases.  Thus,  the functional  losses  accumulate  as  the  disease  progresses  to  a  second  phase (Secondary  Progressive  [SP‐MS]).  In  ten  percent  of  cases,  the  disease  is progressive  from  the  beginning,  without  remissions  (Primary  Progressive  MS [PP‐MS])(2).  In  about  a  quarter  of  patients,  the  progression will  never  lead  to major disability, while in some patients the course of the disease quickly evolves towards major  functional  loss(3),  thereby making  it a highly unpredictable and heterogeneous disease. The precise cause(s) of MS  is/are undetermined, which explains why no curative treatment has so far been developed. There is therefore a huge interest in understanding the immunopathogenesis of MS, as so much is still  to be  learnt about  this autoinflammatory and degenerative disorder of  the CNS. 
1.1.1 Causes Multiple  sclerosis  is  thought  to  occur  in  genetically  predisposed  individuals when favorable environmental triggers are present (4).  Epidemiology shows a North‐South decrease  in MS prevalence  in  the Northern hemisphere,  whereas  there  is  a  South‐North  decrease  in  the  Southern hemisphere, although some disparities exist (1). This variable prevalence is due to  genetic  differences  in  different  populations  but  also  to  other  factors  (as we will  see).  Genetic  predisposition  is  now  beginning  to  be  characterized  with candidate  genes mostly  coding  for  HLA  II  and  I molecules (5).  More  recently, genes coding for other molecules, such as  interleukin receptors were  identified as genetic risk factors thanks to genome‐wide association studies (6)‐(7). The concordance rate for MS in homozygote twins is only 25 % (8) and the fact that  moving  from  a  low‐risk  area  to  a  high‐risk  area  increases  the  risk  of developing MS (9) clearly points towards environmental triggers of the disease. Vitamin D  deficiency  (10)  and  smoking  (11)  have  been  identified  as  two  non‐infectious environmental risk factors of developing MS.  Infections  have  widely  been  studied  as  possible  triggers  for  MS.  Becoming infected with measles mumps,  rubella, and Epstein‐Barr virus at  later ages  is a risk  factor.  In this context  the hygiene hypothesis that has been put  forward  in 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the case of other immune diseases is referred to (12), although of course it has yet  to  be  confirmed.  The most  consistent  infectious  environmental  risk  factor associated  with MS  is  Epstein‐Barr  virus  (EBV)  (13).  EBV  is  a  human  DNA  γ‐herpesvirus,  which  infects  B‐cells,  immortalizes  the  cells  and  then  remains dormant within. IL 10 has a key role to play in this effect(14). T‐cells and NK cells keep  infected  B‐cells  from  starting  monoclonal  proliferation  induced  by  the virus.  In MS patients, EBV seroprevalence  is higher than in control groups (15) and EBV‐specific T‐cells are increased in MS patients when compared to healthy EBV carriers (16). In particular, our research group has shown that the response of EBV‐specific CD8+ T cells was stronger in blood (17) and cerebro‐spinal fluid (CSF)  (18)  of MS  patients.  Thus,  EBV  is  a  possible  trigger  for MS  as well  as  a possible  perpetuating  factor  of  the  disease.  This  may  happen  through  a mechanism  of  molecular  mimicry,  where  T‐cells  recognize  and  react  to  auto‐antigens  (for  example  myelin  antigens)  that  are  similar  to  viral  EBV  antigens expressed on B‐cells by the latent virus(19). 
1.1.2 Pathogenesis The biological course of MS is as variable as its clinical correlate. Autoimmunity causes acute  inflammation of the CNS, which is  followed not only by repair but also by demyelination and, finally, axonal loss.  The start of MS is thought to correspond to an increased arrival of auto‐reactive T‐cells  into  the  CNS.  This  happens  across  the  blood  brain  barrier  (BBB)  using integrins (as VLA‐4 or α4β1 integrin) and adhesion molecules (20).  In the CNS, T‐cells  secrete  cytokines  and  activate  the  local  innate  immune  system  cells, microglia, astrocytes and monocytes. These then induce local  inflammation and are  responsible  for  demyelination  and  axonal  damage.  The  result  is  an infiltration  of  the  white  matter  by  lymphocytes,  activated  microglia  and macrophages.  There  are  a  multitude  of  tissue  injury  patterns  and  as  well  as different  degrees  of  inflammation  seen  in  the  CNS  of  MS  patients,  once  more reflecting the heterogeneity and complexity of this disease (21).  To reach  this point of  self‐destruction,  the auto‐reactive cells must  first escape the  immune  system  tolerance  for  self‐molecules.  This  rupture  of  tolerance  is secondary  to  an  immune  disbalance,  involving  both  the  innate  and  adaptive immune systems, and in the latter system, both cellular and humoral responses (22).  
1.1.3 The role of T‐cells and cytokines The different T‐cell subsets play a key role in MS pathogenesis. They have been studied  mostly  using  the  animal  model  experimental  autoimmune encephalomyelitis (EAE). Let us begin with the T‐helper cells. Historically CD4+ Th1 T‐cells were thought to  be  the major  responsible  T‐cells.  Th1  cells  require  interleukine  (IL)  12  for their differentiation and produce INF, IL‐2 and TNF, cytokines that are correlated with disease activity in MS (23) and attract macrophages.  More recent research has led to the discovery of a new subtype of T‐helper cells referred to as Th17 cells. Th17 cells require IL‐23, TGF,  IL‐6, and IL‐1  for  their development  and  secrete  IL‐17A,  IL‐17F  and  IL‐22.  IL‐17  production  is 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associated with  disease  activity  in  the  CNS  of MS  patients  (24)as well  as with inflammatory  lesions  in  many  other  immune  diseases  (25).  Further  T‐helper cells, such as Th9, which secrete IL‐9 for example (26), have also been described as playing a role in MS. CD4+  Th2  cells  on  the  other  hand,  produce  IL‐4  and  Il‐10.  IL‐10  inhibits  the cytokine production by Th1 cells. In MS patients IL‐10 levels have been observed to  decrease  during  the  time  preceding  relapses  and  to  increase  when  disease activity slows (25). Current  first‐line therapies  in RR‐MS are IFN molecules and Glatiramer Acetate (27) and have clinical benefits, as they both reduce T‐cell proliferation and shift the Th1/Th2 balance towards a Th2 response (3). T‐killer  cells  as  well  have  their  role  to  play:  CD8+  Tc  cells  produce  INFγ  and TNFα. They can directly mediate cell lysis and do also have a pathogenic role in MS (5)(28). 
γδ  T‐cells  are  also  pathogenic  in  EAE  (29)  and  are  present  in  zones  of  active demyelination  in  MS  lesions  (30).  γδ  T‐cells  are  able  to  recognize  antigens directly without MHC presentation. They are  cytotoxic  towards virally  infected cells, tumor cells and CNS glial cells. They are able to lyse oligodendrocytes and secrete INFγ, TNFγ and chemokines (31). Upon stimulation with Il‐23 and IL‐1, γδ T‐cells produce IL‐17(3). 
 




1.2. IL‐26 Cytokines are  thought  to play an  important role  in  the  immunopathogenesis of MS (33). Hereafter, we will  focus on an as‐yet poorly  investigated cytokine:  IL‐26. 
1.2.1 What we know about IL‐26 IL‐26 was discovered in T‐cells transformed by herpes virus saimiri (34). Herpes virus  saimiri  (HSV)  is  a  γ2‐herpes  virus  that  transforms  T‐lymphocytes, immortalizing them in culture(31). Interestingly, in HSV transformed T‐cells, one of the only differences with their parental cells is an over‐expression of the IL‐26 gene (34). Therefore, the HSV‐IL‐26‐ T‐cells' effect appears to be similar to that of the well‐known phenomenon of EBV‐IL‐10‐B‐cells (35). Knowing that EBV has been strongly associated with MS, we were interested in examining whether IL‐26 may play a role in the immunopathogenesis of MS. IL‐26 belongs  to  the  cellular  IL‐10  cytokine  family  of  IL‐10,  IL‐19,  IL‐20,  IL‐22 and IL‐24(36), and is part of  the IL‐20 subgroup (IL‐19,  IL‐22,  IL‐20,  IL‐24 and IL‐26)(37) that is thought to protect tissue from pathogen invasion and to trigger the healing of wounds  (38).  Its  gene  is  located on human  chromosome 12q15, close  to  the  genes  coding  for  IL‐22  and  IFNγ,  both  important  cytokines  in MS. Besides,  IL‐26 was  found  to be often co‐expressed with  IL‐22(39). The gene of IL‐26 has no murine homologue (35). IL‐26  is  expressed by  various  sorts  of  T‐cells  at  low  levels,  especially  by Th17 cells.  It  is  over‐expressed  by  T‐cells  after  HSV  transformation  (as  mentioned above)(39). It is not expressed by B‐cells (34)(36)(40).  IL‐26  signals  through  a  unique  heterodimeric  receptor  composed  of  IL‐10R2 and  IL‐20R1,  a  combination  that  is  specific  to  IL‐26  (41).  As  T‐cells  do  not express  IL‐20R1,  they  probably  are  not  a  target  site  of  IL‐26.  The  complete receptor  complex  is  expressed  in  different  types  of  non‐hematopoietic  tissue, such  as  skin,  colon,  liver,  and  heart,  all  of  which  are  possible  targets  for autoimmune  diseases.  Most  importantly  in  the  case  of  MS,  the  IL‐26  receptor complex is expressed in the cerebellum, the medulla and the spinal cord that are common sites of MS lesions (41)(42).   
1.2.2 What we still need to know about IL‐26 Little is known about the function of IL‐26 although there are some hints as to its role in autoimmune diseases.  Indeed, it has been shown that IL‐26 increases the secretion of IL‐10, IL‐8 as well as  the  surface  expression  of  ICAM‐1  (Inter‐Cellular  Adhesion  Molecule  1)  on epithelial cells of colon carcinoma and keratinocytes (42).  IL‐26 expressing T h 17 cells have been found in increased numbers in active Crohn’s disease (43). In psoriasis,  too,  Th17  cells may  play  a  role,  even  if  IL‐26  is  thought  to  be more prevalent in the colon or the brain than in the skin (37)(44). IL‐26  follows  IL‐22’s  expression pattern  in most  cases  (39)(45)(44).  IL‐22 has been studied to a much greater degree than IL‐26 and is known to participate in the host’s defenses against bacteria, fungi and viruses, but has also been involved in intestinal bowel disease [IBD] and psoriasis pathogenesis, liver protection and 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other immune diseases (38). Nevertheless, there are some important differences between  IL‐26 and  IL‐22:  IL‐26 does not  induce an effect  in keratinocytes, nor does  it  induce  the expression of antimicrobial peptides as  the rest of  the  IL‐20 subgroup  does  (37).  Furthermore,  in  contrast  to  IL‐22,  IL‐26  has  an  anti‐proliferative  effect  on  intestinal  epithelial  cell  lines  (38).  IL‐26  also  has  the particularity  of  being  active  as  a  monomer  or  as  a  dimer  (46)(42)  and  it  is inhibited by heparin (42), which might have its importance in in vitro assays. These various research fields reveal what could be an important role of IL‐26 in inflammatory  diseases  and  show  the  current  need  for  still  more  research  to characterize the expression, function and regulation of IL‐26 in MS.  
1.3 The interest of an ELISA for the detection of IL‐26 The  laboratory  hosting  me  has  recently  found  that  IL‐26  secretion  by  T‐lymphocytes  from  peripheral  blood was  higher  in MS  patients  than  in  healthy controls (Figure 2). These findings encourage us to look further in the direction of a role for IL‐26 in MS. 
 
Figure  2.  Increased  frequency  of  IL­26  secreting  CD8+  T  cells  during  inflammatory  and 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2.1.1 Spiking with recombinant and secreted IL‐26 We used the two different kits on different days, strictly following the producers’ instruction manuals.  All  the  experiences were done  in  duplicates,  and  the PhD student and the research assistant permanently supervised me.  To begin we diluted the kits’ standards at  the different given concentrations to obtain the standard curve. At the same time, we tested the detection of different concentrations  of  recombinant  IL‐26  (R&D,  cat  No.  1375‐IL,  Lot  No.  GVG01), diluted in the kit’s diluent for the USCN kit, and in R10 for the TSZ kit, within the kits’ given range of detection. The PhD student did the experience again. We also e‐mailed one producer (USCN) and called the second one (TSZ), to see if they had 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an element to correct our way of using their kits. They were unable to  indicate any form of misuse. We  then  used  the  two  kits  on  the  supernatant  of  5*106  peripheral  blood mononuclear cells (PBMC) from a healthy donor, kept frozen at ‐70°C and slowly thawed at 37°C. Living cells were sorted out using the violet LIVE/DEAD stain kit (Invitrogen),  and  tested  with  and  without  stimulation  by  phorbol  myristate acetate  and  ionomycin  (PMA/IONO)  for  a  period  of  1,  3,  6  or  12  hours. PMA/IONO stimulation was used  to  increase CD4+ and CD8+  IL‐26 production (as shown by E. Jaquiéry in her thesis and in (49)‐(50)). In the last step we designed a competitive inhibition ELISA. A competition ELISA is  an  assay  in  which  an  antibody  binds  to  the  detected  antigen.  The  antigen therefore no longer binds to the kit’s detection antibody, thereby decreasing its measured  concentrations.  We  tested  the  detection  of  IL‐26  in  supernatant  of PBMC  from  the  same healthy donor,  stimulated 18 hours  in PMA/IONO. To do the competitive inhibition, we added different concentrations (volumes of 0, 2, 5, 5, 10, 20, 50 and 100l antibody in 250l of supernatant) of a polyclonal anti‐IL‐26 antibody (Millipore, cat No. 06‐1081, Lot No. NRG1719646).  
2.1.2 Serum To test the two kits on serum, we used samples from four MS patients and two healthy controls for the TSZ kit and one MS patient and one healthy control for the USCN kit. We chose patients whose sera were kept in our biobank, frozen at ‐20°  C,  and  whose  T‐cells  we  knew  to  produce  IL‐26  thanks  to  previous  tests using flow cytometry. We allowed the serum to thaw at room temperature and used  them  as  soon  as  they  became  liquid. We  strictly  followed  the  instruction manual to test the sera, with and without dilution in phosphate‐buffered saline solution (PBS).  
2.2: Homemade enzyme‐linked immunosorbent assay A short look back at this stage reasonably told us that there was no reliable way of  using  one  or  the  other  commercial  ELISA  kit  (see  the  Results  section).  We decided to use our own homemade IL‐26 detecting ELISA. 
2.2.1 The ELISA 
2.2.1.1 Principle  
Our  homemade  assay  is  an  indirect  sandwich  ELISA,  created  by  using  a  coating 
antibody  (Ab)  and  two  detection  antibodies.  This  ELISA  allows  the  quantitative 
measurement of IL‐26 in a human sample, serum, plasma, CSF, etc.  
To begin with, we  coat  the wells with polyclonal  anti  human  IL‐26 antibodies  (see 
section 2.2.1.1) (Abs). We then saturate non‐specific binding sites with bovine serum 
albumin (BSA) before adding the sample containing IL‐26. Next we add a monoclonal 





managed to stay, bound to  IL‐26. At  last  the AP’s substrate  is added and reveals a 
coloured product. 
Figure 3. Principle of an  indirect sandwich ELISA. Dark blue Y shaped  figures stand  for  the polyclonal goat anti‐human IL‐26 used  for coating. Before adding  the samples, unspecific binding sites are saturated with bovine serum albumin (BSA), not shown. Then the sample containing IL‐26 is added. And IL‐26 binds to the coating anti‐body. Pink disks symbolize IL‐26.   Light blue Y‐shaped figure stand for the monoclonal mouse anti‐IL‐26, the first detection anti‐body. A second biotinylated detection anti‐body, here the green Y‐shaped  figures,  binds  to  the  first  detection  anti‐body.  Extravidine,  the  orange  squares,  tied  to  alkaline phosphatase  (AP)  is  added  and  binds  to  the  biotin  of  the  second  detection  anti‐body.  Then  alkaline phosphatase transforms the substrate (S) added in the last step into a colored product (P) measured by a spectrophotometer. 
This ELISA is a specific and quantitative test. The concentration of IL‐26 in the sample 
is  proportional  to  the  emitted  color.  The  absorbance  has  to  be  read  when  the 





• PBS‐T:  137  mM  NaCl,  1.5  mM  KH2PO4,  8  mM  Na2HPO4,  2.7  mM  KCl, 0.05% Tween 20, pH 7.4 
• Blocking solution: 1% BSA Fluka Cat. # 05477, PBS‐T 
• Standard:  recombinant  IL‐26  diluted  in  PBS‐T‐1%  BSA,  200ng/ml, 100ng/ml,  50ng/ml,  25ng/ml,  12,5ng/ml,  6,25ng/ml,  3,125ng/ml 1,56ng/ml 






• Substrate  solution:  p‐nitrophenyl  phosphate,  Sigma  Cat.  #  104‐105, 1mg/ml in substrate buffer 
2.2.1.3 Set‐up  The protocol was first established to detect IL‐26 in the supernatant of PBMC, on the basis of a protocol for the detection of IL‐24 using other antibodies. We used a  polyclonal  antibody  to  coat  the  wells  to  ensure  that  all  the  IL‐26  would  be captured  while  a  monoclonal  antibody,  which  allows  precise  quantitative measurements, was employed  for  its detection. We extended  the blocking  time and  multiplied  the  numbers  of  washes  after  the  addition  of  AP‐extravidin,  in order to increase specificity. We used recombinant Il‐26 (R&D) for the standard curve and as positive controls; R10 was used for the dilutions and as a negative control. We tested the same protocol on undiluted serum, at two different time points. In the last experiments, we used the ELISA on plasma, using the same protocol. 
2.2.1.4 Final protocol Day 1 1.  Coat  each  well  with  50µl  of  goat  anti  human  IL‐26  diluted  1:25  in  coating solution. Incubate 2 hours at 37°C. 2. Following adsorption, remove the liquid off the well. (Don’t wash.) 3. Block non‐specific  binding  sites by  filling  the wells with 200µl PBS‐T‐1%BSA. 
Incubate for 2 h at 37°C. 4. Wash 3 times with PBS‐T. 5.  Add  standard  and  samples,  100µl  serum/plasma  per  well,  plus  50μl  PBS‐T 1%BSA per well in the samples  Incubate overnight at 4°C. Day 2 6. Wash 3 times with PBS‐T. 7. Add to each well 50µl of the first detection antibody (mouse anti IL‐26) diluted 1:250 in PBS‐T‐1%BSA Incubate for 1 hour at 37°C. 8. Wash 3 times with PBS‐T. 9.  Add  50µl  of  the  second  detection  anti‐body  (goat  anti  mouse  biotinylated antibody) diluted 1:3000 in PBS‐T‐1%BSA  Incubate 1 hour at 37°C. 10. Wash 3 times with PBS‐T. 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11. Add the detection reagent at a dilution 1:10’000 in PBS‐T‐1% BSA Incubate for 30 minutes at 37°C. 10. Wash 6 times with PBS‐T (important). 12. Add 50µl substrate solution per well. Develop at room temperature, away from light, without seal 13.  Read  absorbance  at  405  nm,  simple  filter,  at  15min,  30min,  45min,  60min, 75min, 90min (compare the slopes of the standard curves at these different time points). 
2.2.2 Samples Samples  from  patients  were  taken  from  the  group’s  existing  biobank  after receiving  written  consent  from  patients  in  accordance  with  our  institution’s review  board  guidelines.  PBMC were  kept  frozen  at  ‐70°C,  and  dead  cells  were excluded when thawed using the violet LIVE/DEAD stain kit  (Invitrogen). Serum and  plasma  were  kept  frozen  at  ‐20°C.  PBMC,  serum  and  plasma  from  healthy controls were frozen before use.  The detection in serum was done twice, 3 months apart. The detection in plasma was done at two different time points and by two different people.  
2.2.3 Study subjects 
2.2.3.1 PBMC supernatant We used cells  from two relapsing‐remitting multiple sclerosis (MS) patients,  two secondary‐progressive  MS  patients  and  two  healthy  controls.  Cells  with  and without heparin were incubated for three hours. Half of the cells’ supernatant was then tested after 18 hours of stimulation with PMA/IONO while the other half was tested without. 









Delay between disease 
onset and blood draw in 
years 
RR-MS (24) 38±9.5 7±10.25 
CIS (4) 31.5±5.75 1±0.38 
SP-MS (11) 52±10.25 22±14.25 
PP-MS(3) 47±6 4±2 
OND (4) 61.5±11.75 0.1±1.5 
HC (13) 25±4 n/a 
aMedian±inter-quartile in years   
 
2.3.3 Plasma: first transversal study We included the same patients already enrolled for the serum assay test and used the plasma from the same blood sample used for the serum. For the control group, we included the same OND patients and used the same blood sample used for the serum experiment. We included new healthy controls, because we were not able to take two blood tubes from each healthy control. The median age from the new healthy control group was 25±6 years this time. 
2.2.3.4 Plasma: repetition of the transversal study First another performer did the ELISA again, using the same protocol, on plasma of 70 new study subjects. We enrolled 10 RR‐MS patients, 10 CIS patients, 10 SP‐MS patients, 10 PP‐MS patients, 10 MS patients during a relapse, 10 OND patients and 10 healthy controls.   Then the protocol was applied for the third time, on plasma from  20  study  subjects.  This  time  we  enrolled  the  five  patients  with  positive results in the first serum experiment, along with 3 RR‐MS patients, 3 CIS patients, 3 SP‐MS patients, 3 OND patients and 3 healthy controls.  
2.2.3.5 Plasma: longitudinal study We  included  3  patients  in  the  longitudinal  study.  Two  patients  with  positive results  in  the  first  plasma  assay were  chosen  as well  as  one new patient whose multiple plasma samples were available  to us  in  the biobank.    Samples  from the three  patients  were  taken  at  different  points  in  time  over  the  past  few  years. Regarding  the  first  positive  patient,  14  samples were  taken  between  June  2007 and  June  2011.  With  the  second  positive  patient,  four  samples  were  collected between  August  2008  and  July  2010.  As  for  the  new  patient,  12  samples  were taken between December 2004 and January 2011.  
2.2.4 Statistical analysis Differences  between  two  groups were  tested  using Mann‐Whitney  test,  paired samples were tested with the Wilcoxon test. A p value p<0.05 was considered as significant.  Correlations  were  analyzed  with  the  Spearman’s  test  for  non‐parametric populations. 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3. Results 
3.1. The validity of commercially available ELISA  During  spiking,  the  detected  concentration  did  not  rise  with  the  increase  of recombinant  IL‐26  concentrations  either  in  the  TSZ  or  in  the  USCN  kit.  In  the 
USCN kit,  the recombinant IL‐26 gave a lower absorbance than the zero (Figure 4).  
   
Figure  4.  Spiking  with  recombinant  IL­26.  Il‐26  concentrations  were  calculated  using  the  two  kits’ respective  standard  curves  obtained  with  their  standard  products.  Figure  1a.  USCN  kit  spiking: recombinant  IL‐26  was  detected  in  negative  concentrations  Figure  1b.  TSZ  kit  spiking:  calculated concentrations do not show an increase proportional to the recombinant IL‐26 concentrations.     These  results were worrisome,  strongly  suggesting  that  these  commercial  kits were  utter  failures.  Nonetheless,  we  still  wanted  to  find  out  whether  the commercial kits detected natural IL‐26 secreted by cells, even if recombinant IL‐26  was  not  detected.  Therefore  we  stimulated  PBMC  from  known  IL‐26 producers  with  PMA/IONO.  In  the  end  the  two  kits  detected  an  unknown substance and  the  absorbance was higher  in  the wells with  stimulated  cells  as compared to the ones containing un‐stimulated cells, especially  in the USCN kit (Figure 5). Nevertheless,  results  in  the range of  the micrograms are surprising, very unlikely to result from the detection of a cytokine in blood, usually found in picograms/ml. Now  our  question  was  the  following:  were  the  kits  only  detecting  naturally secreted  IL‐26  and  not  recombinant  IL‐26,  or  were  they  detecting  something else? To answer our question, we designed a competition ELISA as described in 




























Figure  5.  Supernatant  from  PMA/IONO 
stimulated  cells  secrete  something  detected 
by  the  kits.  The  horizontal  bars  represent  the mean  concentration  and  the  standard  deviation interval.  Detected  concentrations  are  higher  in the  stimulated  cells’  supernatant  than  in  that  of the un‐stimulated cells. 
  
 
Figure  6.  Concentration  of  detected  cell­
produced  Il­26  with  rising  anti­IL­26 
concentrations.  The  concentration  of  the detected  substance  does  not  decrease  with  the increase of polyclonal anti‐IL‐26 antibody.  Results obtained with the USCN kit were comparable.  As  a  last  resort, we  decided  to  test  the  two  kits  on  serum,  since  both  of  them were initially designed to detect IL‐26 in serum. We wanted to see whether there was  a  difference  between  the  sera  of  healthy  controls  and  the  sera  of  MS patients. The latter were selected based on the amount of IL‐26 detected on the surface  of  their  T‐cells  using  flow  cytometry  (see  Figure  2).  We  also  tested diluted and undiluted sera.  Neither kit detected a rise of concentration in the presumed IL‐26 patients. The TSZ kit detected  the same concentration whether  the sera were diluted or not.
 
 
Figure  7.  IL­26  detection 

























































































we  would  not  use  the  commercial  kits  to  test  a  large  number  of  samples  as initially planned, since the results would not be reliable. 
3.2. Homemade IL‐26 detection ELISA 






3.2.2  Heparin  does  not  raise  IL‐26  in  PBMC  supernatant  while  stimulation  with 

























































Figure  9.  IL‐26  in  PBMCs’  supernatant, with  and without  3  hours  heparin  and with  (PMA/IONO)  or without 
(unstim) 18 hours PMA/IONO stimulation.  Figure A Heparin does not increase IL‐26 in the supernatant of cells 
from Negative Controls (NC) and MS patients (MS); the difference is the other way round. Figure B: stimulation 










Figure 10.    IL­26 concentration  in  sera  from 42 multiple  sclerosis patients and 17 controls. Figure 


















3.2.5 Our home‐made ELISA proves its reliability  Our  ELISA was  now  ready  to  be  used  on more  samples.  Guillaume  Perriard,  a PhD student in my host laboratory, tested 70 other samples from patients from different MS categories patients and controls. There was no positive result in any of the samples. He decided to test the same plasma samples tested three months earlier  one  more.  He  obtained  the  same  results,  with  the  same  four  patients showing  positive  IL‐26  concentrations  in  their  plasma  on  a  scale  of nanograms/ml.  Detecting the same patients as positive in different samples (serum and plasma), on  different  time  points  (same  samples  tested  months  apart)  and  tested  by different  assay performers,  lead us  to  believe  that  our ELISA’s  results  are  true and reliable, even if IL‐26 secretion seems to be a rare event. 







4.1. Using ELISA to detect IL‐26 in blood of MS patients is possible The first point we would like to make is a commercial one: good marketing and a sleek,  expensive  look  are  not  enough  to  improve  the  poor  quality  of  the industrially‐produced ELISAs. The disappointing results (see results section 3.1) led us to conclude that if you want something to be done well, do it yourself. On a more  serious  note,  the  experiments with  the  commercial  kits  left  us  in  a  very critical mind space regarding our experiments with IL‐26.  As we used our own ELISA in the third experiment on 70 new patients without any  positive  results  (section  3.2.5),  we  first  saw  it  as  a  confirmation  of  well‐placed scepticism in IL‐26 testing. However, initial disbelief in our protocol was definitively  overcome  with  the  experiments  that  followed:  IL‐26  was  always detected with positive results when re‐tested in the positive samples, even with variation  of  standard  curves  and  background,  and  this  on  very  different  time points, with completely different persons using the protocol. This confirms that the results shown by the homemade ELISA are exact and reliable, in sera as well as in plasma (results 3.2.3‐3.2.5). Indeed, serum is the extracellular part of blood after coagulation, while plasma contains fibrinogen and clotting factors. Proteins and  particularly  small  proteins  such  as  cytokines  are  thought  to  be  more concentrated and easier to detect in serum than in plasma. We were pleased to be able to detect the protein in plasma, since plasma samples are generally more available (as mentioned p.19). We  therefore  achieved  the  declared  aim  of  detecting  IL‐26  in  the  blood  of MS patients. We can now discuss the use of this detection and whether it is as useful and promising as proposed in the introduction. 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4.2  IL‐26  detection  in  blood  seems  to  be  specific  to MS patients,  but 
rare Some warnings have to be made before we interpret the results that we obtained with our ELISA. Firstly, criticism about the specificity of the assay could be made. We have no negative control in form of an interleukin close to IL‐26 for example. But using a polyclonal and a monoclonal antibody directed against IL‐26 makes the ELISA a specific method, very unlikely to detect anything else other than IL‐26.  The second warning is about the number of samples: positive IL‐26 samples were rare (5 altogether on a total of 145 patients and controls). Therefore, any conclusions about the secretion pattern of IL‐26 when it is detected as positive have to be considered with caution. Nevertheless, the samples detected as positive where always highly positive with values in the range of nanograms/ml rather then picograms. However, the experiments brought us some new information: First of all, IL‐26 was secreted in patients from all stages of the disease, with no correlation to the duration of the disease (results 3.2.3). This is opposed to the previous  findings  about  IL‐26  being  more  often  secreted  in  SP‐MS  patients (Figure  2). With  IL‐26  being  secreted  in  different  stages  of  the  disease  and  in very few patients, the idea of using it as a marker in MS has to be put aside.  Secondly, with regards to the technique itself, the ELISA does not seem to be the good way of measuring IL‐26. Indeed, even if IL‐26 is secreted into the blood in nanograms,  there  is no clear pattern of  secretion, and  the event appears  to be rare  (results  3.2.6).  It  would  be  of  little  help  to  proceed  to  do  large‐scale screening  of  MS  patients’  blood  samples  with  an  ELISA  before  understanding more about the cytokine and its secretion into blood. IL‐26 seems to be secreted in peaks in some patients, while in others it is secreted continuously. This rises many unanswered questions. What could cause IL‐26 secretion in some patients to  happen  at  certain points  in  time  and  in  others  continuously?    For  example, one  could  imagine  that  an  event  stimulates Th 17  cells  in  a particular way,  or otherwise causes a rupture of the BBB. The idea that IL‐26 is regularly secreted and then bound to surfaces where it stays undetectable in the blood is another possibility. Indeed, IL‐26 is a protein with a large number of positively charged amino  acids  that  can  therefore  easily  bind  itself  to  heparin  (39)  and  possibly even to multiple surfaces such as endothelia or blood cells.  Last  but  not  least,  IL‐26  detection  was  specific  to  MS  patients  in  our  results. Indeed,  in  the 92 MS patients and 53 controls  that we tested, only a handful of MS  patients  (4/92)  and  no  controls  whatsoever  (0/53)  had  positive  IL‐26 concentrations  in  their plasma.  IL‐26 secretion therefore appears  to be specific to MS patients, at least in the samples we tested. Furthermore, when results were positive,  quantities  of  IL‐26 were  high.  All  these  findings  put  together  suggest that  IL‐26  is  secreted  in  relatively  copious  quantities  into  the  blood,  that  this secretion is possible in all phases of the disease, and that it takes place either in very few patients or at rare points in time. But it also means that IL‐26 is a rare event.  This  specific  secretion  in  MS  patients  and  the  fact  that  IL‐26  is  found  in  the peripheral blood may support the idea that IL‐26 has a promising future, despite the fact that its function in MS is almost completely unknown. In conclusion, the 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IL‐26  testing  is  promising,  but  the  use  of  the  ELISA  technique  is  generally inconclusive. Larger testing of patients with this method is not useful at present before we understand more about IL‐26.  
 
4.3 Perspectives The  principle  aim  of  further  experiments  in  this  domain  remains  that  of confirming the importance of IL‐26 in Multiple Sclerosis.  One major problem is that we still lack a firmly established positive control that is  due  to  the  following  reasons.  Firstly,  even  though  we  can  already  detect recombinant IL‐26, or produce IL‐26 in HSV infected T‐cells, we do not yet know how  to  find  a  sample  in  which  we  would  be  sure  to  find  IL‐26  in  natural conditions. Secondly, despite the fact that some patients secrete IL‐26, we do not know  in  which  patients  to  look  for  this  secretion.  Furthermore,  even  if PMA/IONO is known to  increase  the T‐cell  IL‐26 production(49)‐(50), we need to understand how to treat PBMC to provoke their IL‐26 production.  Another major challenge  is  to  find a method sufficiently  sensitive  to be able  to measure the occurrence of  IL‐26 secretion. We know that  it  is detectable using the ELISA, but  this  is of  little use since IL‐26 has here been shown to be rarely secreted into plasma. The use qPCR (quantitative polymerase chain reaction), for example,  could  prove  to  be  a  more  precise,  alternative  method  to  detect  the protein. Finally, an important way of learning more about IL‐26 would be to understand its  role.  It  would  be  very  interesting  to  confirm  which  cells  host  the heterodimeric receptors specific to IL‐26, as well as to observe which genes are up‐regulated  by  the  cytokine.  Understanding  its  function  would  therefore extremely useful in imagining how to detect IL‐26, in which patients, with which samples and using which method. Forthcoming challenges can be summarized as follows: 
• We must  try  to  detect  IL‐26  in  MS  patients  through methods  other than ELISA or  flow cytometry that would allow the detection of RNA rather than the secreted protein, which might be way more sensitive 
• We must  find a confirmed positive control using  the aforementioned method  
• We must define on which cells Il‐26 acts by confirming on which cells the receptor is located and used 





















6. List of abbreviations  AB  Antibody AP  Alkaline Phosphatase BBB  Blood Brain Barrier BSA  Bovin Serum Albumin CIS  Clinically Isolated Syndrom CNS  Central Nervous System DNA  Deoxyribonucleic Acid EAE  Experimental Autoimmune Encephalomyelitis EBV  Epstein Barr Virus ELISA  Enzyme‐linked Immunosorbent Assay HLA  Human Leucocyte Antigen HC  Healthy Control HSV  Herpes Virus Saimiri IBD  Intestinal Bowel Disease ICAM  Intercellular Adhesion Molecule IFN  Interferon IL  Interleukin NC  Negative control NK  Natural Killer MS  Multiple Sclerosis OND  Other Neurological Disease PBMC  Peripheral Blood Mononuclear Cells PBS  Phosphate‐Buffered Saline solution PMA/IONO  Phorbol Myristate Acetate and Ionomycin PP‐MS  Primary Progressive Multiple Sclerosis qPCR  Quantitative Polymerase Chain Reaction RNA  Ribonucleic Acid RR‐MS  Relapsing Remitting Multiple Sclerosis SP‐MS  Secondary Progressive Multiple Sclerosis TGF  Transforming Growth Factor Th  T helper cell TNF  Tumor Necrosis Factor 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